ESMO, a professional organization for medical oncology, has developed a new evidence-based classification to guide research and interpretation of data on treatment de-escalation in oncology. The ESMO framework for the risk-adapted modulation through de-intensification of cancer treatments, published today in Annals of Oncology, offers oncologists, research bodies and regulatory decision-makers a set of common definitions and criteria for driving progress in this important field of treatment personalization.
New ESMO framework to resolve uncertainties about the de-intensification of cancer treatments
ESMO, a professional organization for medical oncology, has developed a new evidence-based classification to guide research and interpretation of data on treatment de-escalation in oncology. The ESMO framework for the risk-adapted modulation through de-intensification of cancer treatments, published today in Annals of Oncology, offers oncologists, research bodies and regulatory decision-makers a set of common definitions and criteria for driving progress in this important field of treatment personalization.